Skip to content


  • Erratum
  • Open Access

Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?

Respiratory Research201718:35

  • Received: 26 January 2017
  • Accepted: 31 January 2017
  • Published:

The original article was published in Respiratory Research 2017 18:19


In the original publication of this article [1], the funding section omitted the following information: This work was funded by Momento Medico srl, which has also contributed to the costs for the literature selection and editorial assistance.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Cardio-thoracic unit and Cystic Fibrosis Adult Center Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
Department of Biomedical Science, Personalized Medicine Clinic: Asthma & Allergy - Humanitas Clinical and Research Center, Humanitas University – Rozzano (Milano), Milan, Italy
Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain


  1. Blasi F, et al. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients? Respir Res. 2017;18:19. doi:10.1186/s12931-017-0506-0.View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s). 2017